Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,701.53 today based on a price of $771.99 for LLY at the time of writing.